Financial Performance - The company's revenue for Q3 2025 was ¥152,671,699.92, representing a 16.04% increase year-over-year, while the year-to-date revenue reached ¥455,071,340.26, up 24.54% compared to the same period last year[6] - The net profit attributable to shareholders for Q3 2025 was -¥21,282,351.06, a decrease of 135.33% year-over-year, and the year-to-date net profit was -¥32,434,878.31, down 129.02% compared to the previous year[6] - The company reported a basic and diluted earnings per share of -¥0.1800 for Q3 2025, reflecting a decline of 130.77% year-over-year[6] - Total operating revenue increased to ¥455,071,340.26, up from ¥365,389,573.73, representing a growth of approximately 24.6% year-over-year[21] - Total operating costs rose to ¥505,144,105.05, compared to ¥407,868,913.77, reflecting an increase of about 24% year-over-year[21] - Net loss for the period was ¥37,430,322.36, worsening from a loss of ¥16,527,962.21 in the previous period[22] - Basic and diluted earnings per share for the current period were -0.28, compared to -0.12 in the previous period[23] Assets and Liabilities - Total assets at the end of Q3 2025 amounted to ¥2,856,762,745.40, an increase of 2.40% from the end of the previous year[6] - Total non-current assets reached ¥2,077,076,297.23, compared to ¥2,019,882,951.74, showing a growth of approximately 2.8%[18] - Total liabilities increased to ¥1,898,857,225.21 from ¥1,775,238,273.87, reflecting a rise of about 7%[19] - The company’s total equity attributable to shareholders decreased by 5.60% to ¥871,396,588.82 compared to the end of the previous year[6] Cash Flow - The net cash flow from operating activities for the first nine months of 2025 was -¥6,166,008.36, a decline of 106.61% compared to the previous year[12] - Cash inflow from operating activities totaled ¥412,169,849.05, a decrease from ¥489,936,789.49 in the previous period[23] - Cash outflow for investing activities was ¥141,243,927.94, significantly lower than ¥328,954,297.32 in the previous period[24] - Cash inflow from financing activities was ¥413,800,628.84, down from ¥610,668,158.75 in the previous period[24] - The ending balance of cash and cash equivalents was ¥81,374,902.32, slightly down from ¥81,618,387.68 in the previous period[24] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 14,193[14] - The largest shareholder, Xi Zubin, holds 31.72% of shares, totaling 36,567,000 shares[14] - The number of restricted shares held by Xi Zubin remains at 27,425,250 shares, with no changes during the period[16] - Li Minglei's restricted shares decreased from 11,528,250 to 10,293,975 shares after 1,234,275 shares were released[16] - There are no changes in the top 10 shareholders due to securities lending or borrowing activities[14] Research and Development - The company’s R&D expenses for the first nine months of 2025 were ¥51,357,520.12, a significant increase of 59.33% compared to ¥32,233,458.68 in the same period last year[11] - Research and development expenses increased significantly to ¥51,357,520.12 from ¥32,233,458.68, marking a rise of approximately 59.5% year-over-year[21] Financial Expenses - The company reported a 153.71% increase in financial expenses, amounting to ¥34,176,897.28, attributed to the cessation of capitalizing certain borrowing costs[11] - Financial expenses surged to ¥34,176,897.28, compared to ¥13,470,914.01, indicating a substantial increase of about 153% year-over-year[21] Other Financial Metrics - The company reported a significant increase in credit impairment losses, totaling ¥6,414,313.63, compared to a gain of ¥1,483,124.03 in the previous period[22] - The company did not undergo an audit for the third quarter financial report[25] - The company reported no net profit from the merged entity prior to the merger[23]
共同药业(300966) - 2025 Q3 - 季度财报